Page last updated: 2024-12-08

1-methyl-4-phenyl-2,3-dihydropyridinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methyl-4-phenyl-2,3-dihydropyridinium is a **heterocyclic compound** that belongs to the class of **dihydropyridines**. It's specifically a derivative of **nicotinic acid**, a vitamin essential for human health.

Here's a breakdown of its importance in research:

**1. Pharmacology and Medicine:**

* **Calcium channel blocker:** 1-methyl-4-phenyl-2,3-dihydropyridinium is the prototype of a class of drugs known as **dihydropyridine calcium channel blockers**. These drugs are widely used to treat **hypertension (high blood pressure)** and **angina (chest pain)**. They work by relaxing blood vessels and reducing the workload of the heart.
* **Drug development:** Its structure is a starting point for developing novel drugs with improved efficacy and fewer side effects. Researchers are constantly working to modify the dihydropyridine structure to create better therapeutic agents.

**2. Neuroscience:**

* **Neurotransmitter release:** 1-methyl-4-phenyl-2,3-dihydropyridinium has been shown to affect the release of neurotransmitters like **acetylcholine**, which plays a crucial role in muscle movement and memory function. This makes it interesting for studying neurological disorders.

**3. Chemistry and Materials Science:**

* **Organic synthesis:** The dihydropyridine ring system is versatile and can be modified to create a wide range of compounds with interesting properties. It's a valuable building block for developing new materials and catalysts.

**In summary:**

1-methyl-4-phenyl-2,3-dihydropyridinium is a key molecule with significant importance in multiple research fields. Its biological activity and structural flexibility make it a valuable tool for developing drugs, understanding neurological processes, and creating innovative materials.

1-methyl-4-phenyl-2,3-dihydropyridinium: RN given from Toxline; RN not in Chemline 4/85 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID150459
CHEMBL ID1182689
SCHEMBL ID561221
MeSH IDM0130518

Synonyms (7)

Synonym
CHEMBL1182689
bdbm50374541
pyridinium, 2,3-dihydro-1-methyl-4-phenyl-
94613-45-3
1-methyl-4-phenyl-2,3-dihydropyridinium
SCHEMBL561221
DTXSID20241554

Research Excerpts

Toxicity

MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is converted by monoamine oxidase B to its putative toxic metabolite MPP+. MPP+ is converted to MPDP+ via MPDP+. MPTP and MPDP can not be oxidized to pyridinium species.

ExcerptReferenceRelevance
"The biochemical and toxic effects of the two monoamine oxidase-generated metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine were investigated using primary cultures of mouse astrocytes."( Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes.
Di Monte, DA; Langston, JW; Wu, EY, 1992
)
0.63
" The 2,2 and 3,3-dimethyl analogs of 1-methyl-4-phenyl-2,3-dihydropyridinium cation which also cannot be oxidized to pyridinium species, reduced striatal dopamine, suggesting that these compounds are toxic in their own right."( On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
Arora, PK; Blue, P; Harik, SI; Iacofano, LA; Sayre, LM; Schmidley, JW, 1987
)
0.55
"MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is converted by monoamine oxidase B to its putative toxic metabolite MPP+ (1-methyl-4-phenylpyridinium ion) via MPDP+ (1-methyl-4-phenyl-2,3-dihydropyridinium ion)."( Comparative toxicity and antioxidant activity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B-generated metabolites in isolated hepatocytes and liver microsomes.
Di Monte, D; Ekström, G; Sandy, MS; Smith, MT, 1987
)
0.47
" Addition of MPP+ itself is toxic to hepatocytes but only after a long lag period, which presumably reflects its limited access to the cell and its relatively slow intracellular accumulation."( Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes.
Castagnoli, N; Di Monte, D; Ekström, G; Shinka, T; Smith, MT; Trevor, AJ, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (42.22)18.7374
1990's19 (42.22)18.2507
2000's4 (8.89)29.6817
2010's3 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.51 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]